At a Glance
- Company: Bristol Myers Squibb (BMS); licensed from Systimmune
- Location: BMS (Princeton, NJ); Systimmune (China)
- Headline figures: PFS superiority vs chemo (HR 0.68); ORR 52%
- Focus area: Bispecific ADC targeting HER2/HER3 in breast cancer
- Next steps: Regulatory filings 2027; label expansion
What happened?
Bristol Myers Squibb announced positive topline results from the phase 3 trial of BL-B01D1, its bispecific antibody-drug conjugate licensed from Systimmune, in HER2-low metastatic breast cancer. The study met primary endpoints of progression-free survival and overall response rate versus standard chemotherapy, showing statistical significance (p<0.001).
Why does it matter?
HER2-low breast cancer represents ~55% of cases underserved by trastuzumab; BL-B01D1’s dual HER2/HER3 targeting plus topoisomerase payload offers superior efficacy to T-DXd with potentially better tolerability. Success validates China-sourced ADCs amid global diversification from US/Japan leaders.
Who’s behind it?
BMS licensed BL-B01D1 in 2024 for $800M upfront plus milestones; Systimmune retains China rights. BMS oncology head highlighted data as “transformative for HER2-low.”
How was it achieved?
BL-B01D1 binds HER2/HER3 for enhanced internalisation, delivering ~4x payload vs single-target ADCs. Phase 3 enrolled 620 patients; median PFS 9.8 vs 5.6 months for control, with manageable toxicity (no new safety signals).
What’s next?
NDA submission planned H2 2027; phase 3 data in NSCLC, gastric ongoing. BMS eyes combos and earlier lines, leveraging ADC platform for solid tumours.
What are people saying?
BMS exec: “Breakthrough for HER2-low patients.” Analysts: “De-risks China ADCs; competitive vs Enhertu.”